Headshot of Laszlo Mechtler

Laszlo Mechtler, MD
Chief Medical Officer
DENT Neurologic Institute
SPEAKER
ADVISORY BOARD MEMBER
POSTER PRESENTER
MEDICINE

A Crossover Study Evaluating the PK Parameters of a Novel Cannabis Delivery Method as Compared to an Oil-Based Oral Tincture

In the context of drug development, there are a multitude of factors that one must consider but perhaps no one single factor is more important than the method of administration. Common modalities include oral consumption (swallowing), sublingual administration, inhalation, transdermal absorption, or injection, each of which has its own distinct advantages and disadvantages. Selection of the appropriate delivery modality is paramount in drug development as not all administration methods are suitable for the drug in question and/or the desired outcome. Some drugs; however, are available in several modalities, one such example being cannabinoid-based therapies which can be found in inhaled, sublingual, orally consumed, transdermal, injectable, and rectally administered formats. The wide range of drug delivery options for cannabinoid-based therapies is largely driven by consumer preferences, medical conditions, and desired effects.

This large variation in administration modality; however, also results in a large variation in pharmacokinetic profiles in addition to efficacy. To address this variation we subjected an oil-based cannabis preparation to a unique drug delivery system called self-nanoemulsifying drug delivery systems (SNEDDS) and compared the pharmacokinetic outcomes to the same cannabis dose administered via oral tincture. This technology is designed to enhance the bioavailability and solubility of poorly water-soluble drugs such as cannabis preparations. SNEDDS are anhydrous homogenous liquid mixtures consisting of oil, surfactant, drug and coemulsifier or solubilizer, which spontaneously form oil-in-water nanoemulsion. Thus, may significantly improve therapeutic outcomes by facilitating better and faster absorption as well as improved systemic availability.

Cannabis in the Treatment of Motor Neuron Disease: A Retrospective Study
Background: MND’s such as ALS have been a growing topic of discussion in recent years due to the significance of the disease state. On a yearly basis, there are over 30,000 active cases and $370 million is spent to treat these diseases in the United States alone. With no known cure and limited treatment options available these diseases are typically fatal within 5 years of diagnosis. Due to the grim prognosis of these diseases, clinicians, scientists and patients alike have a keen interest in identifying treatment options for these diseases. One such treatment potential option that has emerged is medical cannabis, which recent scientific literature has shown to be an effective treatment option for many of the comorbidities and symptoms of MNDs.
Medical Cannabis as an Adjunctive Treatment for Epilepsy: A Retrospective Study
Background: Defined as recurrent episodes of involuntary movement involving part or all of the body Epilepsy is among the most common non-communicable neurological diseases globally. Epilepsy is estimated to affect over 50 million adults worldwide including around 3.4 million active cases in the US alone. Although there are many treatment options available for epilepsy, these interventions often fail to provide complete control and come with adverse effects and other concerns. As a result, there has been an expanding search for different therapies including cannabinoid-based therapies some of which have received FDA approval. The FDA approval of cannabinoid-based therapy and increased access to MC across the US has facilitated a substantial line of inquiry regarding the use of full-spectrum cannabis products in comprehensive treatment plans of epilepsy patients.
BIO
Dr. Laszlo Mechtler is Professor of Neurology and Oncology at the State University of New York at Buffalo, Chief Medical Officer of the Dent Neurologic Institute, the largest out-patient neuroscience center in the United States and as the Chief of Neurology and Oncology and Roswell Park Cancer Center. He holds board certifications in Neurology, Neuroimaging, Neuro-Oncology and Headache Medicine. His training includes institutions such as MD Anderson, the State University of New York at Buffalo, and Semmelweis University. He is a past president of the American Society of Neuroimaging (ASN) and the Hungarian Medical Association of America (HMAA). He was the guest editor of the 2009, 2014 and 2020 editions of Neurology Clinics on ‘Neuroimaging”. He served on the Executive Committee for BrainPAC through the American Academy of Neurology (AAN).

He currently serves on the Board of Directors for the International Headache Society (IHS) and Genomate Health. Dr. Mechtler has published some of the first major retrospective research trials on Medical Marijuana in headaches and various neurologic disorders. He is the Director of the DENT Cannabis Clinic, which has more than 15,000 patients certified through the NYS MMJ program and continues to grow each day. He has developed medical cannabis formulations (CBD/THC) tailored to specific neurologic disorders including migraine, sleep and anxiety. Dr. Mechtler is also the Founder/Chief Medical Officer for the MIND Institute in Budapest, Hungary. Dr. Mechtler lectures both nationally and internationally and is recognized as a leader in the fields of Neuroimaging, Headache Medicine, Neuro-Oncology, and Medical Cannabis.

View CannMed Resources Below:

ATTENDANCE IS LIMITED. THE OPPORTUNITIES ARE NOT.

Image